BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 21444870)

  • 1. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.
    Lorch A; Bascoul-Mollevi C; Kramar A; Einhorn L; Necchi A; Massard C; De Giorgi U; Fléchon A; Margolin K; Lotz JP; Germà-Lluch JR; Powles T; Kollmannsberger C; Beyer J
    J Clin Oncol; 2011 Jun; 29(16):2178-84. PubMed ID: 21444870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
    Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
    Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.
    Pico JL; Fadel E; Ibrahim A; Bourhis JH; Droz JP
    Bull Cancer; 1995; 82 Suppl 1():56s-60s. PubMed ID: 7542945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features.
    De Giorgi U; Rosti G; Salvioni R; Papiani G; Ballardini M; Pizzocaro G; Marangolo M
    Urol Oncol; 2011; 29(3):284-90. PubMed ID: 19556152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
    Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ
    J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial.
    Lorch A; Kleinhans A; Kramar A; Kollmannsberger CK; Hartmann JT; Bokemeyer C; Rick O; Beyer J
    J Clin Oncol; 2012 Mar; 30(8):800-5. PubMed ID: 22291076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.
    Kondagunta GV; Bacik J; Sheinfeld J; Bajorin D; Bains M; Reich L; Deluca J; Budnick A; Ishill N; Mazumdar M; Bosl GJ; Motzer RJ
    J Clin Oncol; 2007 Jan; 25(1):85-90. PubMed ID: 17194908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.
    Lorch A; Kollmannsberger C; Hartmann JT; Metzner B; Schmidt-Wolf IG; Berdel WE; Weissinger F; Schleicher J; Egerer G; Haas A; Schirren R; Beyer J; Bokemeyer C; Rick O;
    J Clin Oncol; 2007 Jul; 25(19):2778-84. PubMed ID: 17602082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.
    ; Lorch A; Beyer J; Bascoul-Mollevi C; Kramar A; Einhorn LH; Necchi A; Massard C; De Giorgi U; Fléchon A; Margolin KA; Lotz JP; Germa Lluch JR; Powles T; Kollmannsberger CK
    J Clin Oncol; 2010 Nov; 28(33):4906-11. PubMed ID: 20956623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor?
    Banna GL; De Giorgi U; Ferrari B; Castagna L; Alloisio M; Marangolo M; Rosti G; Santoro A
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1085-91. PubMed ID: 17084372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).
    Haugnes HS; Laurell A; Stierner U; Bremnes RM; Dahl O; Cavallin-Ståhl E; Cohn-Cedermark G
    Acta Oncol; 2012 Feb; 51(2):168-76. PubMed ID: 22175254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of the dose of etoposide in the initial treatment of metastatic germ cell tumors and advances in management of patients that relapse.
    Marwaha S; Venner PM; North SA
    Can J Urol; 2007 Oct; 14(5):3692-6. PubMed ID: 17949524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.
    Narayan V; Gunnarsson O; Hwang WT; Squillante CM; Nathanson KL; Stadtmauer EA; Vaughn DJ
    Clin Genitourin Cancer; 2016 Dec; 14(6):524-529. PubMed ID: 27083130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
    Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
    N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
    Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
    Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.
    Margolin KA; Doroshow JH; Frankel P; Chow W; Leong LA; Lim D; McNamara M; Morgan RJ; Shibata S; Somlo G; Twardowski P; Yen Y; Kogut N; Schriber J; Alvarnas J; Stalter S
    Biol Blood Marrow Transplant; 2005 Nov; 11(11):903-11. PubMed ID: 16275593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
    Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
    J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients.
    De Giorgi U; Rosti G; Papiani G; Marangolo M
    Haematologica; 2002 Jan; 87(1):95-104. PubMed ID: 11801470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience.
    Motzer RJ; Bajorin DF; Vlamis V; Weisen S; Bosl GJ
    Semin Oncol; 1992 Dec; 19(6 Suppl 12):8-11. PubMed ID: 1336624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.